Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine plus Brentuximab Vedotin in HL and PTCL
NCT02499627Phase 2Terminated
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Dec 2015
- Primary completion
- Sep 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL), sponsored by Fondazione Italiana Linfomi. Primary endpoint: Overall Objective Response Rate at 1 year. Started Dec 2015; status: terminated.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT02499627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02499627.